Johnson & Johnson, Imerys ordered to pay additional US$80mln in punitive damages in talc-cancer case
A New Jersey state court jury awarded the damages today, the report says
Company
Johnson & Johnson
NYSE:JNJ
Johnson & Johnson is a diversified healthcare products company. The company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through two segments: Pharmaceutical and MedTech.
152 stories · page 2 of 2
Johnson & Johnson, Imerys ordered by court to pay at least US$37mln in asbestos suit
Investment banker claimed asbestos in talc product caused cancer
New tax law drags Johnson & Johnson’s fourth quarter into red territory but sales up
The new tax law saw the company make a provisional tax charge of US$13.27bn
Johnson & Johnson, Chesapeake Energy, Verizon Communications and more - PRE-MARKET
Wall Street shares are seen starting mixed - what else is happening in pre-market deals?
Hardware & electrical equipment
Abbott Laboratories, Apple Inc, Lennar and Wynn Resorts Ltd - PRE-MARKET
Proactive takes a look at pre-market trade in New York, and picks out some highlights
Nasdaq lower but Dow Jones and S&P 500 gain at close
US stocks were mixed at the close, with the Nasdaq in the red
Johnson & Johnson ups full year guidance after third quarter beats market expectations
In the third quarter, revenue from its largest unit, the pharmaceutical arm, surged 15%, boosted by the US$30bn acquisition of Swiss biotech Actelion earlier this year and new additions including Darzalex
Goldman Sachs Group, Morgan Stanley, Harley Davidson and more - PRE-MARKET
We take a look at what's moving the needle in pre-market deals in New York
Johnson & Johnson enjoys positive noises from analysts
Swiss bank UBS repeated a 'buy' on the shares, targeting $148, while Stifel says it's poised to accelerate growth in the second half.
Gilead Sciences, Kite Pharma, Amazon.com, Hurricane Harvey and more - PRE-MARKET
We look at what's coming up before the bell this week in New York trade
Goldman Sachs Group, Johnson & Johnson, Harley-Davidson and more
In pre-market trade, shares in motorcycle giant Harley-Davidson Inc dropped almost 9%
Johnson & Johnson shares advance as second quarter beats market expectations
Johnson & Johnson shares were changing hands at US$133.50 each, up 1%.
Johnson & Johnson may seek to set aside talc cancer judgements after Supreme Court ruling
Over 1,000 plaintiffs have sued J&J in the state of Missouri but most are from outside of the state.
ShareRoot shares ride higher on signing Johnson & Johnson
Global sales pipeline for the ShareRoot platform continues to strengthen.
GSK, AT&T and Verizon join advertising boycott on Google over extremist content
Google's promise to crack down on adverts from appearing alongside extremist content has failed to reassure clients
Aspiring to AAA seems as simple as ABC for Google owner Alphabet
Alphabet the owner of Google, now has a Standard & Poor’s credit rating on a par with the United States of America
US shares mark fresh record highs as banks price in earlier rate hike
US stocks marked a fresh raft of record highs on Wednesday as the Fed brought forward the prospect of rate hikes in the world’s biggest economy and bank stocks hit record highs
Johnson & Johnson nips ecological doomsday scenario in the (cotton) bud
Trending this morning: J&J abandons use of plastic in cotton buds; Valentine's Day; Rolls-Royce; Credit Suisse
AbbVie's revenue miss clouds strong Humira US sales
AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its
US stocks close mixed after Trump mulls 20% border tax
US stocks closed mixed on Thursday, with the Dow and Nasdaq marking fresh record highs but the S&P 500 doing as much – before heading lower after US President Donald Trump mooted that he was weighing up a 20% border tax on Mexican imports t
J&J, world's largest healthcare firm, agrees US$30bn deal to buy Actelion, Europe’s biggest biotech group
J&J is paying $280 a share in cash for Actelion, retaining the Swiss firm's commercially available treatments for rare diseases such as pulmonary arterial hypertension.
US shares end up as oil investors crowd out depressed pharma post-Trump speech
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
US stocks end rallying year on a lower note
US stocks ended the year on a low point, as the Dow ebbed further away from 20,000 and other tickers also printed sharp declines
US stocks close lower on Thursday as Dow gives up the spirit of 20,000
On the last full day’s trading before the Christmas holiday, US stocks ended lower on Thursday as markets began to wind down
Volte face: Johnson & Johnson re-enters acquisition talks with Swiss biotech firm Actelion
J&J abruptly bowed out of the bid process for Actelion last week after the Swiss firm said that it was “engaged in discussions with another party”.
GlaxoSmithKline’s fast-growing HIV drug business gets another boost
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Johnson & Johnson shares up despite $1bn penalty over hip implants
Johnson & Johnson shares rose on Friday despite a federal court ruling in Dallas on Thursday which ordered the pharma and its DePuy Orthopaedics unit to pay more than $1bn to six Californian plaintiffs who said they were injured by Pinnacle
US small-caps among the top risers after Trump victory
US stocks snapped back from initial losses to close Wednesday higher and the Dow even managed an intraday record peak, while small-caps had one of their best days in 14 years, after Donald Trump and the Republicans’ sweep into office
Pfizer’s spoiler on Johnson & Johnson’s earnings rally
The world’s largest healthcare company Johnson & Johnson’s third-quarter earnings per share came in 3 cents higher than analysts’ forecasts. But Pfizer said it will launch a cheaper competing product to J&J's flagship drug Remicade
US stocks gain in healthy sector rally
US stocks ended higher on Tuesday with a boost from high drama in the healthcare sector
TRACON gets US$5mln and licensing deal from Janssen
Tracon expects to initiate a Phase 1/2 proof-of-concept (POC) clinical trial for one of the molecules, TRC253, in prostate cancer applications in the first half of next year.
J&J advances after results beat expectations
Sales and earnings guidance has now been upgraded.
US stocks close lower over oil, Brexit and the Fed meeting this week
US stocks closed lower on Monday as weaker oil prices, worries over a possible UK Brexit vote and anxieties ahead of the Federal Reserve rate meeting midweek, unsettled the bourse
Stocks in consolidation mode
Signs of stability returning to the battered Chinese economy buoyed markets
Johnson & Johnson Q1 earnings bode well for Medtech season
Johnson & Johnson first quarter results bode well for the Medtech industry's earnings season, broker Wedbush says
US stocks cling onto gains as oil prices rise, China seen stabilising
US stocks close higher as oil price gains on the back of signs of stability returning to the battered Chinese economy
Stocks starts higher on an oil price rise and earnings beats
In the small cap world, the Russell 2,000, was around seven points higher at 1,146.
Wall Street shares poised to build on Monday’s gains
Wall Street shares are set for a higher open after a good day yesterday, which saw stocks close at their highest levels of the year.
Stocks start higher on an oil price rise and earnings beats
In the small cap world, the Russell 2,000, was around seven points higher at 1,146.
GlaxoSmithKline gets shot in arm but M&A talk trundles on
Drug company boosted 2015 revenues and achieved better-than-expected dip in earnings
Archive
FTSE100 falls as oil hopes rise; Glaxo bid talk swirls
Britain's blue chips closed the afternoon session lower after uninspiring UK economic data and as energy powerhouse Centrica weighed.
Trending: Johnson & Johnson mulling Glaxo bid?
Open Outcrier tweets that there is “vague takeover chatter” concerning a takeover of drugs giant GlaxoSmithKline by healthcare behemoth Johnson & Johnson.
Wall Street rebounds sharply amid oil rally
An oil rally sent both Brent and U.S. crude briefly above $32 a barrel.
US Risers & Fallers: Morgan Stanley, UnitedHealth, J&J, Amarantus, Avant, Payment Data
Below are some of the main news-driven share price changes as at 11:33 a.m. in New York.
Equities take a pause for breath
Molson Coors is a bright spot on bid speculation, but otherwise it has been a dull day for stocks.
Investments and investor services
Stocks tread water despite Chinese trade data disappointment
Shares are holding their ground, helped by a little bit of bid speculation
Archive
Winning run set to come to an end after Chinese imports shocker
After a long winning streak, investors are set to bank profits following some worrying trade data overnight from China.
J&J shares seesaw on mixed results
The healthcare-docused consumer products group could buy back up to 3.8% of its shares in issue.
Wall Street gains for 4th day on oil rebound; JPMorgan rises
Wall Street headed for its first four-day winning run since January, after a landmark nuclear deal between Tehran and six global powers left sanctions on Iran in place for now, while weaker-than-expected retail sales spurred bets on timing
Wall Street poised to open lower as oil prices retreat on Iran nuclear deal
Wall Street is set to open lower today as investor focus shifted from Greece to the U.S. earnings season and after an Iranian nuclear deal stoked fears of oil-market oversupply. Futures for the Dow Jones Industrial Average slipped 0.1 perce